Evotec announces sale of API manufacturing facility to Monacum Partners

New ownership committed to maintaining and growing the business

06-Nov-2024 - Evotec SE has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec’s “Priority Reset” initiative launched in April 2024, which aims to foster ...

Evotec and Pfizer collaborate to advance drug discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases

11-Jul-2024 - Evotec SE announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases. The research will be carried out at ...

Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration

Identification of novel therapeutic targets in obesity and metabolic diseases

31-May-2024 - Evotec SE announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert (the private subsidiary of Inserm) to identify novel therapeutic targets and diagnostic and prognostic markers in ...

Evotec appoints Dr Christian Wojczewski as CEO

25-Apr-2024 - The Supervisory Board of Evotec SE has appointed Dr Christian Wojczewski as the Company’s new Chief Executive Officer (“CEO”), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January. Dr Mario Polywka, who has led Evotec as ...

Evotec announces CEO transition

Dr Werner Lanthaler to step down as CEO

08-Jan-2024 - Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue to serve until the end of his current term (March 2026), for personal reasons. The Supervisory Board has accepted his resignation from his ...

Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes

08-Nov-2023 - Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...

New incubator to promote drug discovery and create new therapeutics companies in Singapore

Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch "65LAB"

06-Oct-2023 - Evotec SE announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new ...

Evotec provides update on financial impact of cyber-attack

Productivity was affected throughout the entire second quarter

31-Jul-2023 - Evotec SE announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. For the current fiscal year, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 – 840 m); unpartnered R&D is expected in a range of € 60 – 70 ...

Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

24-Mar-2023 - Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB ...